dual agonist glp 1 GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes The GLP1-ELP-FGF21 dual-agonist fusion protein

Over 30 years ago scientists discovered the potential of Gila monster venom as a treatment for type 2 diabetes.

For patients, oral therapies promise greater convenience, improved adherence, and broader access, particularly for those reluctant to use injectables

1 (2025 ): 400- Glycated hemoglobin (HbA1c) remains the gold standard for assessing long-term glycemic control, reflecting the average plasma glucose over the preceding 812 weeks

Area covered Therefore, this review aims to summarize recent strategies to address the challenges associated with the oral delivery of GLP-1RAs

Supports appetite control and helps reduce food cravings, naturally